These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2890299)

  • 1. Understanding the use of behavioral rating scales in studies evaluating the efficacy of antianxiety and antidepressant drugs.
    Fankhauser MP; German ML
    Am J Hosp Pharm; 1987 Sep; 44(9):2087-100. PubMed ID: 2890299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New anxiolytic drugs: methodological issues].
    Ginestet D; Corruble E
    Encephale; 1993; 19(6):627-37. PubMed ID: 12404782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using longitudinal data from a clinical trial in depression to assess the reliability of its outcome scales.
    Laenen A; Alonso A; Molenberghs G; Vangeneugden T; Mallinckrodt CH
    J Psychiatr Res; 2009 Apr; 43(7):730-8. PubMed ID: 18986657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Self-rating scales in schizophrenia: validity assessment of the Paranoid-Depression Scale (PD-S), the Frankfurt Self-feeling Scale (FBS) and of two visual analogy scales].
    Schaeffer E; Wciórka J
    Psychiatr Pol; 2003; 37(2):293-314. PubMed ID: 12776660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Translation and validation of a French version of the Young Mania Rating Scale (YMRS)].
    Favre S; Aubry JM; Gex-Fabry M; Ragama-Pardos E; McQuillan A; Bertschy G
    Encephale; 2003; 29(6):499-505. PubMed ID: 15029084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome criteria in antidepressant drug trials: self-rating versus observer-rating scales.
    Möller HJ
    Pharmacopsychiatry; 1991 May; 24(3):71-5. PubMed ID: 1891483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of evaluation scales in psychopharmacology].
    Spriet A; Fermanian J; Simon P
    Encephale; 1978; 4(2):119-29. PubMed ID: 688971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects.
    Pae CU; Mandelli L; Kim TS; Han C; Masand PS; Marks DM; Patkar AA; Steffens DC; De Ronchi D; Serretti A
    Biomed Pharmacother; 2009 Mar; 63(3):228-35. PubMed ID: 18502089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of a self-report depression symptom scale for identifying remission in depressed outpatients.
    Zimmerman M; Posternak MA; McGlinchey J; Friedman M; Attiullah N; Boerescu D
    Compr Psychiatry; 2006; 47(3):185-8. PubMed ID: 16635646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antidepressants consumption in the global population in France].
    Olié JP; Elomari F; Spadone C; Lépine JP
    Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
    Lee JH; Dunner DL
    Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a physician rating scale for investigation of antianxiety effects of drugs [proceedings].
    Free SM; Overall JE
    Psychopharmacol Bull; 1977 Apr; 13(2):8-11. PubMed ID: 16312
    [No Abstract]   [Full Text] [Related]  

  • 14. The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity.
    Rothschild AJ
    Compr Psychiatry; 2008; 49(5):508-13. PubMed ID: 18702938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of generalized anxiety: new pharmacologic approaches].
    Boulenger JP
    Encephale; 1995; 21(6):459-66. PubMed ID: 8674471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
    Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confounding by severity and indication in observational studies of antidepressant effectiveness.
    Patten SB
    Can J Clin Pharmacol; 2008; 15(2):e367-71. PubMed ID: 18840922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of placebo-controlled trials with bupropion.
    Zung WW
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):104-14. PubMed ID: 6406436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reliability in the evaluation of anxiety].
    Lara MD; de la Fuente JR
    Acta Psiquiatr Psicol Am Lat; 1987 Sep; 33(3):209-18. PubMed ID: 3442250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.